NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research ChannelBioSpace Collaborative Employers
 Post Job | Search Resumes | Login

  News | News By Subject | News By Date | Search News
Print   Email 

Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Localized Fat Reduction
3/9/2010

SAN DIEGO, March 9, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. LIPO-102 is being studied for the treatment of exophthalmos using abdominal fat as a surrogate for periorbital fat. LIPO-102 was well-tolerated when administered weekly for 4 weeks into the subcutaneous abdominal fat of healthy subjects. Dose- and time-related reductions in abdominal circumference and skin-fold thickness measures were observed one (Week 5) and four (Week 8) weeks after the treatment period. A reduction of 3.47 cm (p=0.017) in mean abdominal circumference was observed at Week 8 in subjects receiving the optimal dose of LIPO-102 once per week for 4 weeks.

Read at GlobeNewswire
 
 Read Article at  Related Companies  News Categories
Lithera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES